186 related articles for article (PubMed ID: 23978005)
1. Lymphatic transport of puerarin occurs after oral administration of different lipid-based formulations to unconscious lymph duct-cannulated rats.
Zhou A; Lu T; Wang L; Lu C; Wang L; Wan M; Wu H
Pharm Dev Technol; 2014 Sep; 19(6):743-7. PubMed ID: 23978005
[TBL] [Abstract][Full Text] [Related]
2. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems.
Wu H; Zhou A; Lu C; Wang L
Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284
[TBL] [Abstract][Full Text] [Related]
3. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs.
Lespine A; Chanoit G; Bousquet-Melou A; Lallemand E; Bassissi FM; Alvinerie M; Toutain PL
Eur J Pharm Sci; 2006 Jan; 27(1):37-43. PubMed ID: 16198549
[TBL] [Abstract][Full Text] [Related]
4. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
[TBL] [Abstract][Full Text] [Related]
5. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
Hauss DJ; Fogal SE; Ficorilli JV; Price CA; Roy T; Jayaraj AA; Keirns JJ
J Pharm Sci; 1998 Feb; 87(2):164-9. PubMed ID: 9519148
[TBL] [Abstract][Full Text] [Related]
6. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model.
Griffin BT; O'Driscoll CM
J Pharm Pharmacol; 2006 Jul; 58(7):917-25. PubMed ID: 16805951
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of microemulsion enhancing the oral bioavailability of puerarin: comparison between oil-in-water and water-in-oil microemulsions using the single-pass intestinal perfusion method and a chylomicron flow blocking approach.
Tang TT; Hu XB; Liao DH; Liu XY; Xiang DX
Int J Nanomedicine; 2013; 8():4415-26. PubMed ID: 24277986
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration.
Luo CF; Yuan M; Chen MS; Liu SM; Zhu L; Huang BY; Liu XW; Xiong W
Int J Pharm; 2011 May; 410(1-2):138-44. PubMed ID: 21392565
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
Porter CJ; Charman SA; Charman WN
J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067
[TBL] [Abstract][Full Text] [Related]
10. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol.
Caliph SM; Faassen FW; Porter CJ
J Pharm Pharmacol; 2014 Oct; 66(10):1377-87. PubMed ID: 24821499
[TBL] [Abstract][Full Text] [Related]
11. RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model.
Dong Z; Guo J; Xing X; Zhang X; Du Y; Lu Q
Biomed Pharmacother; 2017 May; 89():297-304. PubMed ID: 28236703
[TBL] [Abstract][Full Text] [Related]
12. [Absorption transport mechanism of puerarin oil-in-oil nanoemulsion].
Pan E; Wu H; Lu C; Gui S; Wang L
Zhongguo Zhong Yao Za Zhi; 2010 Oct; 35(20):2674-8. PubMed ID: 21246816
[TBL] [Abstract][Full Text] [Related]
13. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.
Khoo SM; Shackleford DM; Porter CJ; Edwards GA; Charman WN
Pharm Res; 2003 Sep; 20(9):1460-5. PubMed ID: 14567642
[TBL] [Abstract][Full Text] [Related]
14. Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat.
Tu L; Yi Y; Wu W; Hu F; Hu K; Feng J
Int J Pharm; 2013 Dec; 458(1):135-40. PubMed ID: 24120729
[TBL] [Abstract][Full Text] [Related]
15. Influence of bile on the absorption of halofantrine from lipid-based formulations.
Holm R; Tønsberg H; Jørgensen EB; Abedinpour P; Farsad S; Müllertz A
Eur J Pharm Biopharm; 2012 Jun; 81(2):281-7. PubMed ID: 22465095
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs.
Wang W; Chen N; Shen X; Cunningham P; Fauty S; Michel K; Wang B; Hong X; Adreani C; Nunes CN; Johnson CV; Yin KC; Groff M; Zou Y; Liu L; Hamuro L; Prueksaritanont T
Drug Metab Dispos; 2012 May; 40(5):952-62. PubMed ID: 22328584
[TBL] [Abstract][Full Text] [Related]
17. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
[TBL] [Abstract][Full Text] [Related]
18. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
Cai Q; Deng X; Li Z; An D; Shen T; Zhong M
Drug Deliv; 2016; 23(1):147-53. PubMed ID: 24786483
[TBL] [Abstract][Full Text] [Related]
19. Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues.
Caliph SM; Faassen WA; Vogel GM; Porter CJ
Curr Drug Deliv; 2009 Aug; 6(4):359-66. PubMed ID: 19534711
[TBL] [Abstract][Full Text] [Related]
20. Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats.
Sun M; Zhai X; Xue K; Hu L; Yang X; Li G; Si L
Eur J Pharm Sci; 2011 Jun; 43(3):132-40. PubMed ID: 21530655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
